In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Direct-to-Consumer Advertising

Executive Summary

Drug company spending on direct-to-consumer advertising is soaring and could reach $10 billion, or as much as 30% of all promotional spending, by 2005, if current trends continue. But some powerful groups, most notably, doctors, pharmacists and managed care organizations, have begun to express their concern, worried that such advertising inappropriately influences patient prescribing.

You may also be interested in...

Big Pharma Continues to Rely on Marketing to Consumers

DTC advertising for prescription drugs is alive and well. Companies spent $2.16 billion through the end of October 2002--$216 million per month--a 4.4% increase over the monthly industry spend rate from 2001. In a year characterized by belt-tightening decisions, this step-up in spending reflects just how crucial it is for pharmaceuticals to steer consumers towards high-margin drugs.

For Devices, an Elusive Consumer Appeal

While pharmaceutical companies have begun to explore the blow-out potential of a direct to consumer appeal in quality of life issues, medical device firms have sat on the sidelines. They've targeted seriously ill patients on the outer fringes of conditions like obesity and erectile dysfunction, but as of yet, haven't really gone after the huge central market.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts